Abstract: The present invention relates to a pharmaceutical composition for transdermal administration comprising a conjugate of methotrexate and PTD (protein transduction domain). In accordance with the present invention, the methotrexate, which is widely used for the treatment of psoriasis, rheumatoid and inflammation, etc., can be delivered transdermally to a local part of a patient body, in order to minimize the side effect of the methotrexate.

Abstract: The present invention relates to methods of delivering nucleic acids into cells using a nucleic acid binding molecule containing a multimeric or spacer-incorporated protein transduction domain (PTD). The invention also relates to novel compositions that contain a nucleic acid complexed or conjugated with a nucleic acid binding molecule. The nucleic acid binding molecule may contain a multimeric or spacer-incorporated PTD, and may further contain a nucleic acid binding region. The nucleic acid complexes or conjugations of the present invention may be employed to inhibit expression of a target gene, and/or determine the function of a target gene.

Abstract: The present invention relates to pharmaceutical compositions for treating diseases and conditions caused by ischemia. The pharmaceutical compositions contain a conjugate of a phospholipase (PL) polypeptide and a protein transduction domain (PTD). PLC-? plays a major role in the regulation of cytosolic calcium levels. During myocardial ischemia, cytosolic calcium accumulation mediates pathogenic changes. According to the present invention, ischemic diseases or conditions leading to hypoxia in tissues, such as the heart and the brain, can be prevented or alleviated by administration of a PTD-PL conjugate.

Abstract: Disclosed herein are a novel pharmaceutical composition for inhibiting autoimmune diseases, allergic diseases and inflammatory diseases, which contains a conjugate of Foxp3 and PTD (protein transduction domain), and a delivery method thereof. According to the disclosed invention, Foxp3-PTD treats and inhibits autoimmune diseases by effectively inhibiting the activation of T cells in a mouse autoimmune disease model.

Abstract: The present invention relates to methods for delivery of fusion polypeptides into cells. Methods are provided for local delivery of fusion polypeptides, e.g., through the skin, eye and the airway, to prevent allergic inflammation, airway hyper-responsiveness and to block T cell activation. Methods for delivery of fusion polypeptides to suppress graft rejection are also provided.

Abstract: This invention relates to a novel Biomolecule Transduction Motif (BTM), Mph-1 peptide (Mph-1-BTM), which has the potential to transduce many biological response modifiers effectively into the cytoplasm, intracellular organelles or nucleus of prokaryotic or eukaryotic cells in vivo and in vitro, and the related technological methods using Mph-1-BTM. This Mph-1-BTM can be used in the development of new recombinant protein vaccines or DNA/RNA vaccines, gene and protein therapy, production of pharmacologically or medicinally useful proteins, or pharmaco-medicinal drug therapy.

Abstract: The present invention relates to methods of delivering nucleic acids into cells using a nucleic acid binding molecule containing a multimeric or spacer-incorporated protein transduction domain (PTD). The invention also relates to novel compositions that contain a nucleic acid complexed or conjugated with a nucleic acid binding molecule. The nucleic acid binding molecule may contain a multimeric or spacer-incorporated PTD, and may further contain a nucleic acid binding region. The nucleic acid complexes or conjugations of the present invention may be employed to inhibit expression of a target gene, and/or determine the function of a target gene.

Abstract: The present invention relates to pharmaceutical compositions for treating diseases and conditions caused by ischemia. The pharmaceutical compositions contain a conjugate of a phospholipase (PL) polypeptide and a protein transduction domain (PTD). PLC-? plays a major role in the regulation of cytosolic calcium levels. During myocardial ischemia, cytosolic calcium accumulation mediates pathogenic changes. According to the present invention, ischemic diseases or conditions leading to hypoxia in tissues, such as the heart and the brain, can be prevented or alleviated by administration of a PTD-PL conjugate.

Abstract: The present invention relates to a pharmaceutical composition for transdermal administration comprising a conjugate of methotrexate and PTD (protein transduction domain). In accordance with the present invention, the methotrexate, which is widely used for the treatment of psoriasis, rheumatoid and inflammation, etc., can be delivered transdermally to a local part of a patient body, in order to minimize the side effect of the methotrexate.

Abstract: The present invention relates to a pharmaceutical composition for treating heart diseases, neurodegenerative diseases, and diseases and conditions caused by apoptosis, which contains a conjugate of a heat shock protein (Hsp) and a protein transduction domain (PTD). According to the present invention, PTD-Hsp70 effectively suppresses apoptosis under low-oxygen conditions.

Abstract: This invention is about a novel Biomolecule Transducton Motif (BTM), Sim-2 peptide, which has a potential to transduce many biological response modifiers effectively into the cytoplasm, intracellular organelles or nucleus of prokaryotic or eukaryotic cells in vivo and in vitro, and the related technological methods using Sim-2 BTM. This Sim-2 BTM can be used for Drug Delivery System, development of new recombinant protein vaccines or DNA/RNA vaccines, gene and protein therapy, production of pharmacologically or medicinally useful proteins or pharmacomedicinal drug therapy.

Abstract: The present invention relates to methods for delivery of fusion polypeptides into cells. Methods are provided for local delivery of fusion polypeptides, e.g., through the skin, eye and the airway, to prevent allergic inflammation, airway hyper-responsiveness and to block T cell activation. Methods for delivery of fusion polypeptides to suppress graft rejection are also provided.

Abstract: This invention relates to a novel Biomolecule Transduction Motif (BTM), Mph-1 peptide, which has the potential to transduce many biological response modifiers effectively into the cytoplasm, intracellular organelles or nucleus of prokaryotic or eukaryotic cells in vivo and in vitro, and the related technological methods using Mph-1 BTM. This Mph-1 BTM can be used in the development of new recombinant protein vaccines or DNA/RNA vaccines, gene and protein therapy, production of pharmacologically or medicinally useful proteins, or pharmaco-medicinal drug therapy.

Abstract: This invention is about a novel Biomolecule Transducton Motif (BTM), Sim-2 peptide, which has a potential to transduce many biological response modifiers effectively into the cytoplasm, intracellular organelles or nucleus of prokaryotic or eukaryotic cells in vivo and in vitro, and the related technological methods using Sim-2 BTM. This Sim-2 BTM can be used for Drug Delivery System, development of new recombinant protein vaccines or DNA/RNA vaccines, gene and protein therapy, production of pharmacologically or medicinally useful proteins or pharmacomedicinal drug therapy.

Abstract: This invention is about a novel Biomolecule Transduction Motif (BTM), Mph-1 peptide, which has a potential to transduce many biological response modifiers effectively into the cytoplasm, intracellular organelles or nucleus of prokaryotic or eukaryotic cells in vivo and in vitro, and the related technological methods using Mph-1 BTM. This Mph-1 BTM can be used for Durg Delivery System, development of new recombinant protein vaccines or DNA/RNA vaccines, gene and protein theraphy, production of pharmacologically or medicinally useful proteins or pharmacomedicinal drug therapy.